Tags

Type your tag names separated by a space and hit enter

Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
Nutr Metab Cardiovasc Dis. 2009 Nov; 19(9):613-9.NM

Abstract

BACKGROUND AND AIMS

Reduced high density lipoproteins (HDL) and increased oxidative stress are features of type 2 diabetes. Myeloperoxidase is an oxidative enzyme partly associated with HDL and causing HDL dysfunction. It is an independent risk factor for cardiovascular disease. Paraoxonase-1 is an HDL-associated enzyme that protects against cardiovascular disease and is reduced in diabetes. The present study examined if serum myeloperoxidase was (i) increased in type 2 diabetes, (ii) correlated with paraoxonase-1 activity.

METHODS AND RESULTS

The study was based on cross-sectional analyses of serum myeloperoxidase and paraoxonase-1 in type 2 diabetic patients and non-diabetic participants, with and without cardiovascular disease. Serum myeloperoxidase concentrations were not increased in type 2 diabetic patients without cardiovascular disease compared to non-diabetic controls. They were significantly higher in type 2 patients and non-diabetic patients with angiographically confirmed coronary disease. HDL-associated myeloperoxidase was correlated with serum myeloperoxidase (r=0.80, p<0.001) but not HDL-cholesterol (r=0.08) or apolipoprotein AI (r=0.08). Multivariate analyses showed serum myeloperoxidase to be an independent determinant of paraoxonase activities (arylesterase, p=0.024; paraoxonase, p=0.026).

CONCLUSIONS

Myeloperoxidase is an independent, negative determinant of paraoxonase-1 activity, which may be one mechanism by which it promotes HDL dysfunction and increases cardiovascular risk. Increased serum myeloperoxidase is not a feature of type 2 diabetes in the absence of overt cardiovascular disease. The level of HDL-associated myeloperoxidase is determined by the serum concentration of the enzyme suggesting that, in the context of reduced HDL concentrations in diabetic patients, myeloperoxidase may have a greater impact on HDL function.

Authors+Show Affiliations

Service of Endocrinology, Diabetes and Nutrition, Department of Internal Medicine, Faculty of Medicine, Geneva University, Geneva, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19201174

Citation

Jornayvaz, F R., et al. "Myeloperoxidase and Paraoxonase-1 in Type 2 Diabetic Patients." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 19, no. 9, 2009, pp. 613-9.
Jornayvaz FR, Brulhart-Meynet MC, James RW. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2009;19(9):613-9.
Jornayvaz, F. R., Brulhart-Meynet, M. C., & James, R. W. (2009). Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 19(9), 613-9. https://doi.org/10.1016/j.numecd.2008.12.005
Jornayvaz FR, Brulhart-Meynet MC, James RW. Myeloperoxidase and Paraoxonase-1 in Type 2 Diabetic Patients. Nutr Metab Cardiovasc Dis. 2009;19(9):613-9. PubMed PMID: 19201174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. AU - Jornayvaz,F R, AU - Brulhart-Meynet,M-C, AU - James,R W, Y1 - 2009/02/06/ PY - 2008/07/24/received PY - 2008/12/01/revised PY - 2008/12/02/accepted PY - 2009/2/10/entrez PY - 2009/2/10/pubmed PY - 2010/1/26/medline SP - 613 EP - 9 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 19 IS - 9 N2 - BACKGROUND AND AIMS: Reduced high density lipoproteins (HDL) and increased oxidative stress are features of type 2 diabetes. Myeloperoxidase is an oxidative enzyme partly associated with HDL and causing HDL dysfunction. It is an independent risk factor for cardiovascular disease. Paraoxonase-1 is an HDL-associated enzyme that protects against cardiovascular disease and is reduced in diabetes. The present study examined if serum myeloperoxidase was (i) increased in type 2 diabetes, (ii) correlated with paraoxonase-1 activity. METHODS AND RESULTS: The study was based on cross-sectional analyses of serum myeloperoxidase and paraoxonase-1 in type 2 diabetic patients and non-diabetic participants, with and without cardiovascular disease. Serum myeloperoxidase concentrations were not increased in type 2 diabetic patients without cardiovascular disease compared to non-diabetic controls. They were significantly higher in type 2 patients and non-diabetic patients with angiographically confirmed coronary disease. HDL-associated myeloperoxidase was correlated with serum myeloperoxidase (r=0.80, p<0.001) but not HDL-cholesterol (r=0.08) or apolipoprotein AI (r=0.08). Multivariate analyses showed serum myeloperoxidase to be an independent determinant of paraoxonase activities (arylesterase, p=0.024; paraoxonase, p=0.026). CONCLUSIONS: Myeloperoxidase is an independent, negative determinant of paraoxonase-1 activity, which may be one mechanism by which it promotes HDL dysfunction and increases cardiovascular risk. Increased serum myeloperoxidase is not a feature of type 2 diabetes in the absence of overt cardiovascular disease. The level of HDL-associated myeloperoxidase is determined by the serum concentration of the enzyme suggesting that, in the context of reduced HDL concentrations in diabetic patients, myeloperoxidase may have a greater impact on HDL function. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/19201174/Myeloperoxidase_and_paraoxonase_1_in_type_2_diabetic_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(08)00238-X DB - PRIME DP - Unbound Medicine ER -